Leibniz Institute for Immunotherapy, Division of Immunology, 93053 Regensburg, Germany.
Leibniz Institute for Immunotherapy, Division of Immunology, 93053 Regensburg, Germany; Chair for Immunology, University of Regensburg, 93053 Regensburg, Germany.
Trends Immunol. 2023 Jun;44(6):468-483. doi: 10.1016/j.it.2023.04.005. Epub 2023 Apr 25.
Regulatory T (Treg) cells ensure tolerance against self-antigens, limit excessive inflammation, and support tissue repair processes. Therefore, Treg cells are currently attractive candidates for the treatment of certain inflammatory diseases, autoimmune disorders, or transplant rejection. Early clinical trials have proved the safety and efficacy of certain Treg cell therapies in inflammatory diseases. We summarize recent advances in engineering Treg cells, including the concept of biosensors for inflammation. We assess Treg cell engineering possibilities for novel functional units, including Treg cell modifications influencing stability, migration, and tissue adaptation. Finally, we outline perspectives of engineered Treg cells going beyond inflammatory diseases by using custom-designed receptors and read-out systems, aiming to use Treg cells as in vivo diagnostic tools and drug delivery vehicles.
调节性 T（Treg）细胞可确保对自身抗原的耐受性，限制过度炎症，并支持组织修复过程。因此，Treg 细胞目前是治疗某些炎症性疾病、自身免疫性疾病或移植排斥反应的有吸引力的候选物。早期临床试验已经证明了某些 Treg 细胞疗法在炎症性疾病中的安全性和有效性。我们总结了工程 Treg 细胞的最新进展，包括用于炎症的生物传感器的概念。我们评估了 Treg 细胞工程的可能性，包括影响稳定性、迁移和组织适应性的新型功能单元的修饰。最后，我们概述了通过使用定制设计的受体和读出系统来超越炎症性疾病的工程 Treg 细胞的前景，旨在将 Treg 细胞用作体内诊断工具和药物输送载体。
